

## Abstract

Inhibitors of type 2 methionine aminopeptidases ("MetAP2"), specifically dominant negative variants of MetAP2, both polypeptides and encoding polynucleotides, are provided.

5 Also provided are methods of treating subjects suffering from cancer, diseases mediated by the immune system or opportunistic infections using inhibitors of MetAP2. Also provided are high throughput screens and assays to detect and identify inhibitors of MetAP2 and downstream effectors of MetAP2.